# Effect Of Semaglutide In Coronary Atheroma Plaque

Study · id `cardio:ct-nct05071417` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT05071417](<https://clinicaltrials.gov/study/NCT05071417>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT05071417

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 120 participants.

## Technical summary

Registry record NCT05071417. Allocation not applicable; no masking; primary purpose treatment. Start 2021-11 (anticipated); primary completion 2024-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 120 participants (planned count; ClinicalTrials.gov record NCT05071417, source copy `cardio:ctgov-nct05071417-2021-10-08`, retrieved 2026-10-26)
- Planned start: 2021-11 (anticipated) (ClinicalTrials.gov record NCT05071417, source copy `cardio:ctgov-nct05071417-2021-10-08`, retrieved 2026-10-26)
- Primary completion: 2024-12 (anticipated) (ClinicalTrials.gov record NCT05071417, source copy `cardio:ctgov-nct05071417-2021-10-08`, retrieved 2026-10-26)
- Completion: 2025-12 (anticipated) (ClinicalTrials.gov record NCT05071417, source copy `cardio:ctgov-nct05071417-2021-10-08`, retrieved 2026-10-26)
- Countries: Not reported
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct05071417-2021-10-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effect Of Semaglutide In Coronary Atheroma Plaque
- Acronym: SEPLA
- Condition: Atheroscleroses, Coronary
- Intervention (Drug): Semaglutide
- Lead sponsor: Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)

## Provenance

Content hash: 6e7e32540677e24131445da601f0c587c6a72b993e29896eb249fe3ee099dfe3
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
